CRISPR Therapeutics AG — Director's Dealing 2019

Dec 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-12-03

Reporting Person: Ho Tony W (Executive VP, Head of R&D)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-03	Restricted Stock Units	$	A	40000	Acquired		Common Shares (40000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022